Patents by Inventor Hélène M. Faessel

Hélène M. Faessel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PROSTATE CANCER
    Publication number: 20250082632
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 25, 2024
    Publication date: March 13, 2025
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MACLEAN, Lynn SEELY, Paul N. MUDD, Jr., Hélène M. FAESSEL
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20250057839
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 5, 2024
    Publication date: February 20, 2025
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MACLEAN, Lynn SEELY, Paul N. MUDD, JR., Hélène M. FAESSEL
  • Treatment of prostate cancer
    Patent number: 12144809
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2024
    Date of Patent: November 19, 2024
    Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. Maclean, Lynn Seely, Paul N. Mudd, Jr., Hélène M. Faessel
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20240358700
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 31, 2024
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JONHSON, David B. MACLEAN, Lynn SEELY, Paul N. MUDD, JR., Hélène M. FAESSEL
  • Treatment of prostate cancer
    Patent number: 12097198
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: September 24, 2024
    Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. Maclean, Lynn Seely, Paul N. Mudd, Jr., Hélène M. Faessel